NCT04044560View on ClinicalTrials.gov

Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

February 2, 2022

Study Completion Date

February 2, 2022

Conditions
B-cell Adult Acute Lymphoblastic LeukemiaStem Cell LeukemiaMinimal Residual Disease
Interventions
BIOLOGICAL

blinatumomab

Continuous intravenous infusion

Trial Locations (3)

V5Z1M9

Vancouver General Hospital - Leukemia/Bone Marrow Transplant Program, Vancouver

V5Z4H4

BC Children's Hospital, Vancouver

B3H 2Y9

QEII - Health Sciences Centre, Halifax

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

University of British Columbia

OTHER